oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis
Ctr Assessment Med Technol Örebro.ORCID iD: 0000-0003-3253-8967
Orebro Univ Hosp, Ctr Assessment Med Technol Orebro, S-70185 Orebro, Sweden.;Orebro Univ Hosp, Dept Lab Med, S-70185 Orebro, Sweden..
2013 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 40, no 11, 1770-1780 p.Article, review/survey (Refereed) Published
Abstract [en]

Purpose Neuroendocrine tumours (NET) are uncommon and may be localized in many different places in the body. Traditional imaging has mainly been performed with CT and somatostatin receptor scintigraphy (SRS). Recently, it has become possible to use somatostatin receptor PET/CT (SMSR PET) instead, which might improve diagnostic quality. To evaluate the diagnostic quality of SMSR PET we performed a meta-analysis as an update of a previous study published in 2012. A literature search was performed searching MEDLINE, Embase and five other databases with a combination of the expressions "PET", "positron emission tomography", "neuroendocrine" and "NET". The search was updated to 31 December 2012. Studies were selected which evaluated the sensitivity and specificity of SMSR PET for NET in the thorax or abdomen with a study size of at least eight patients. The methodological quality of the included studies was evaluated with QUADAS-2. Eight studies fulfilled the inclusion criteria and were selected for final analysis, and 14 articles from a previous meta-analysis were added for a total of 22 articles. A total of 2,105 patients were included in the studies, an increase from 567 in the previous meta-analysis. The pooled sensitivity was 93 % (95 % CI 91 - 94 %) and specificity 96 % (95 % CI 95 - 98 %). The area under the summary ROC curve was 0.98 (95 % CI 0.95 - 1.0). In the previous meta-analysis the pooled sensitivity was 93 % (95 % CI 91 - 95 %) and specificity 91 % (95 % CI 82 - 97 %). SMSR PET has good diagnostic performance for evaluation of NET in the thorax and abdomen, better than SRS which has been the previous standard method. This meta-analysis gives further support for switching to SMSR PET.

Place, publisher, year, edition, pages
Springer, 2013. Vol. 40, no 11, 1770-1780 p.
Keyword [en]
PET, Positron emission tomography, Somatostatin, Neuroendocrine, NET
National Category
Cancer and Oncology Radiology, Nuclear Medicine and Medical Imaging
Identifiers
URN: urn:nbn:se:oru:diva-56539DOI: 10.1007/s00259-013-2482-zISI: 000325128800015PubMedID: 23873003OAI: oai:DiVA.org:oru-56539DiVA: diva2:1082687
Available from: 2017-03-17 Created: 2017-03-17 Last updated: 2017-03-24Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Geijer, HåkanBreimer, Lars H.
In the same journal
European Journal of Nuclear Medicine and Molecular Imaging
Cancer and OncologyRadiology, Nuclear Medicine and Medical Imaging

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 48 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf